二甲双胍是一种抗菌药物吗？

StephenW

Diabetes Metab Res Rev. 2017 Dec 22. doi: 10.1002/dmrr.2975. [Epub ahead of print]
Is Metformin Poised for a Second Career as an Antimicrobial?Malik F1, Mehdi SF1, Ali H1, Patel P1, Basharat A1, Kumar A1, Ashok F1, Stein J1, Brima W1, Malhotra P1,2, Roth J1,3.
Author information
1Laboratory of Diabetes and Diabetes-related Research, Feinstein Institute for Medical Research, Manhasset, NY, United States.2Division of Infectious Diseases.3Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Manhasset, NY, United States.

AbstractBACKGROUND: Metformin, a widely used anti-hyperglycemic, has a good safety profile, reasonably manageable side-effects, is inexpensive and causes a desirable amount of weight loss. In four studies of patients with tuberculosis (one prospective and three retrospective), metformin administration resulted in better outcomes. In mice with several models of endotoxemia, metformin diminished levels of pro-inflammatory cytokines and improved survival. Laboratory studies showed effectiveness of the drug on multiple pathogens, including Trichinella spiralis, Staphylococcus aureus, Pseudomonas aeruginosa, Hepatitis B virus, Hepatitis C virus and human immunodeficiency virus. Metformin administration in humans and mice produced major changes in the composition of the gut microbiota. These recently discovered microbe-modulating properties of the drug have led investigators to predict wide therapeutic utility for metformin. The recent easing in FDA guidelines regarding administration of metformin to patients with kidney disease, and reduced anxiety about patient safety in terms of lactic acidosis, increase the probability of broadening of metformin's usage as a treatment for infectious agents. In this text we review articles pertinent to metformin's effects on microorganisms, both pathogens and commensals. We highlight the possible role of metformin in a wide range of infectious diseases and a possible expansion of its therapeutic profile in this field.
METHODS: A systematic review was done of PubMed indexed articles that examined the effects of metformin on a wide range of pathogens.
RESULTS: Metformin was found to have efficacy as an antimicrobial agent in patients with tuberculosis. Mice infected with Trypanosomiasis cruzi had higher survival when also treated with metformin. The drug in vitro was active against Trichinella spiralis, Staphylococcus aureus, Pseudomonas aeruginosa and Hepatitis B virus. In addition there is emerging literature on its role in sepsis. We conclude that metformin may have a potential role in the therapy of multiple infectious diseases.


Copyright © 2017 John Wiley & Sons, Ltd.



KEYWORDS: Hepatitis B; Metformin; Trypanosomiasis cruzi; antimicrobial; sepsis; tuberculosis

PMID:29271563DOI:10.1002/dmrr.2975

• 
  


• 
  

StephenW

Diabetes Metab Res Rev. 2017 Dec 22. doi：10.1002 / dmrr.2975。 [电子版提前打印]
二甲双胍是一种抗菌药物吗？
Malik F1，Mehdi SF1，Ali H1，Patel P1，Basharat A1，Kumar A1，Ashok F1，Stein J1，Brima W1，Malhotra P1,2，Roth J1,3。
作者信息

1
    糖尿病和糖尿病相关研究实验室，美国纽约曼哈塞特市芬斯坦医学研究所。
2
    传染病科。
3
    Donald和Barbara Zucker医学院，位于美国纽约Manhasset的Hofstra / Northwell。

抽象
背景：

广泛使用的抗高血糖药二甲双胍具有良好的安全性，合理可控的副作用，价格便宜并且导致理想的体重减轻量。在四项关于结核病患者的研究（一项前瞻性和三项回顾性研究）中，二甲双胍的治疗效果更好。在具有几种内毒素血症模型的小鼠中，二甲双胍降低促炎细胞因子的水平并改善存活。实验室研究表明该药物对包括旋毛虫，金黄色葡萄球菌，铜绿假单胞菌，乙型肝炎病毒，丙型肝炎病毒和人类免疫缺陷病毒在内的多种病原体的有效性。人和小鼠中的二甲双胍给药在肠道微生物群的组成上产生了重大变化。最近发现的这些药物的微生物调节特性已经导致研究人员预测二甲双胍的广泛治疗效用。最近FDA关于向肾病患者服用二甲双胍指南的缓解以及降低患者对乳酸酸中毒安全性的焦虑，增加了二甲双胍扩大治疗感染性药物的可能性。在本文中，我们回顾了有关二甲双胍对微生物，病原体和共生体的影响的文章。我们强调了二甲双胍在广泛的传染性疾病中可能发挥的作用，并可能扩大其在这一领域的治疗情况。
方法：

对PubMed索引文章进行了系统回顾，检查了二甲双胍对广泛病原体的影响。
结果：

发现二甲双胍在肺结核患者中具有作为抗微生物剂的功效。当用二甲双胍治疗时，用克氏锥虫病感染的小鼠具有更高的存活率。该药体外抗旋毛虫，金黄色葡萄球菌，绿脓杆菌和乙型肝炎病毒。此外还有关于其在败血​​症中作用的新兴文献。我们得出结论：二甲双胍可能在多种传染病的治疗中具有潜在的作用。

版权©2017 John Wiley＆Sons，Ltd.
关键词：

乙型肝炎;二甲双胍;克鲁斯锥虫病抗菌;败血症;结核

结论：
    29271563
DOI：
    10.1002 / dmrr.2975

windu

要不买点来吃一下，有没有剂量说明？

neilhbver

实验显示，不同的动物服用二甲双胍都活的更长寿更健康